Compare GH & CHWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GH | CHWY |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 13.5B |
| IPO Year | 2018 | 2019 |
| Metric | GH | CHWY |
|---|---|---|
| Price | $110.09 | $32.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 22 |
| Target Price | ★ $99.48 | $45.86 |
| AVG Volume (30 Days) | 1.9M | ★ 8.0M |
| Earning Date | 02-19-2026 | 12-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | $902,569,000.00 | ★ $12,584,235,000.00 |
| Revenue This Year | $35.00 | $8.66 |
| Revenue Next Year | $26.80 | $8.62 |
| P/E Ratio | ★ N/A | $64.64 |
| Revenue Growth | ★ 30.38 | 10.00 |
| 52 Week Low | $34.80 | $29.83 |
| 52 Week High | $113.91 | $48.62 |
| Indicator | GH | CHWY |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 43.40 |
| Support Level | $106.42 | $31.51 |
| Resistance Level | $113.91 | $33.97 |
| Average True Range (ATR) | 3.97 | 0.93 |
| MACD | 0.63 | -0.04 |
| Stochastic Oscillator | 77.16 | 39.37 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending time developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.